National Medical Research Center for Children's Health, Russian Federation
Quick facts
Marketed products
- cream 0.1% methylprednisolone aceponate
- Cyclosporine therapy · Immunology
Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines. - Dupilumab therapy · Immunology
- Methotrexate therapy · Oncology, Immunology, Rheumatology
Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation. - Mycophenolate mofetil therapy
- Ustekinumab Injection · Immunology
Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, reducing inflammatory immune responses.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- National Medical Research Center for Children's Health, Russian Federation portfolio CI brief
- National Medical Research Center for Children's Health, Russian Federation pipeline updates RSS
Frequently asked questions about National Medical Research Center for Children's Health, Russian Federation
What are National Medical Research Center for Children's Health, Russian Federation's marketed drugs?
Top marketed products include cream 0.1% methylprednisolone aceponate, Cyclosporine therapy, Dupilumab therapy, Methotrexate therapy, Mycophenolate mofetil therapy, Ustekinumab Injection.
Related
- cream 0.1% methylprednisolone aceponate
- Cyclosporine therapy · Immunology
- Dupilumab therapy · Immunology
- Methotrexate therapy · Oncology, Immunology, Rheumatology
- Mycophenolate mofetil therapy
- Sector hub: All tracked pharma companies